In this conversation with Kristin Begley, chief commercial officer at Capital Rx, we discussed the company’s recent rebrand ...

Enrollment in Medicare Advantage Special Needs Plans (SNPs) has grown steadily since becoming permanent in 2018, now ...

Panelists discuss how the expanding treatment landscape for Crohn’s disease includes multiple mechanisms of action such as anti-tumor necrosis factor (TNF) agents, anti-integrin agents, interleukin ...

Panelists discuss how maintaining patients on effective single therapies for Crohn’s disease is preferable to switching ...

An expert discusses how primary and secondary prevention differ in atherosclerotic cardiovascular disease, with secondary prevention targeting patients who have already had events such as heart ...

The deuterated form of deupirfenidone produced favorable results in an open-label extension study. Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease marked by irreversible ...

Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for ...

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing ...

If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 ...

We’ll be back on Monday morning with more fresh content!

The short-term study is believed to be the first to evaluate both interventions combined for people with mental illness.

Evkeeza is now approved for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients as young as 1 year ...